General Information


DRAVP ID  DRAVPe00519

Peptide Name   C34

Sequence  WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL

Sequence Length  34

UniProt ID  No entry found

Source  Synthetic construct

Other Link  DRAVPa0875



Activity Information


Target Organism  HIV

Assay  MAGI assay

Activity 

  • [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=7.3± 2.5 nM);
  • HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=15± 2.3 nM);
  • HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=23 ± 5.0 nM);
  • HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=19 ±4.7 nM).
  • [Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=7.2±0.2 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=18.8± 1.6 nM);
  • HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=7.6±0.2 nM);

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

  • No cytotoxicity information or data found in the reference(s) presented in this entry

Binding Target  membrane

Mechanism  The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion.



Structure Information


PDB ID  None

Predicted Structure Download  DRAVPe00519

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L



Physicochemical Information


Formula  C184H280N50O64S

Absent amino acids  ACFGPV

Common amino acids  E

Mass  4248.6

Pl  4.21

Basic residues  3

Acidic residues  8

Hydrophobic residues  9

Net charge  -5

Boman Index  -10170

Hydrophobicity  -127.06

Aliphatic Index  80.29

Half Life 

  •     Mammalian:2.8 hour
  •     Yeast:3 min
  •     E.coli:2 min

Extinction Coefficient cystines  12490

Absorbance 280nm  378.48

Polar residues  9



Literature Information


Literature 1

Title   Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Pubmed ID   19073606

Reference   J Biol Chem. 2009 Feb 20;284(8):4914-20.

Author   Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.

DOI   10.1074/jbc.M807169200

Literature 2

Title   Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.

Pubmed ID   27795416

Reference   J Virol. 2016 Dec 16;91(1):e01445-16.

Author   Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. 

DOI   10.1128/JVI.01445-16